Article
The FDA-approved 3-bag intravenous n-acetylcysteine regimen for acetaminophen toxicity is being challenged by a simpler approach.
When it comes to medication regimens, simplicity is often the key to minimizing errors.
With regards to intravenous (IV) n-acetylcysteine for acetaminophen toxicity, the 3-bag infusion protocol is particularly prone to errors. These errors can occur as a result of a treatment team member’s unfamiliarity with this antidotal therapy, and they often manifest as delays between the end of one infusion and the beginning of another.
In one study, the 3-bag regimen was associated with up to a 33% incidence of errors.1
The search for a simplified regimen has been underway for some time.
Previous studies have investigated the safety and effectiveness of administering the total regimen dose of 300 mg/kg with various infusion strategies. Like much of emergency medicine and toxicology data, however, the extrapolation of these data was limited by the small sample sizes and often retrospective, observational, single-center study design.
While challenges in conducting higher methodological studies exist, new observational data continue to accumulate with promising results. The most recent attempt at a simplified regimen investigated a novel IV n-acetylcysteine infusion strategy in a critically understudied population: pediatrics.2
The authors of this study used a 2-bag infusion method consisting of a 150 mg/kg loading dose followed by a maintenance infusion of 15 mg/kg/hr until acetaminophen concentrations were <10 mg/L and liver enzyme concentrations were within normal limits, or at least trending in that direction.
Data were collected in a retrospective manner in pediatric patients treated with this regimen for acute or chronic overdoses of acetaminophen at a single institution over a 4-year period. Patients were excluded if they had a history of chronic liver disease or initiation of any other n-acetylcysteine regimen.
The final analysis included a total of 59 patients who ranged in age from 2 months to 18 years (median of 14 years). The degree of severity assessed by Rumack-Matthew nomogram noted that most patients fell into the probable risk and possible risk categories [21 (38%) and 22 (39%) respectively].
The effectiveness of the 2-bag n-acetylcysteine regimen was described in descriptive clinical outcomes.
Most patients (49) ingested acetaminophen intentionally, while 10 ingested it unintentionally. Additionally, 35 patients ingested other medications.
The authors considered diphenhydramine co-ingestions independently from the other co-ingestants listed because of the drug’s known ability to prolong gastrointestinal transit time for acetaminophen, which leads to higher acetaminophen concentrations that persist.
Only 2 patients developed hepatotoxicity defined as alanine transaminase or aspartate transaminase >1000 units/L; however, no patients developed manifestation of liver failure, encephalopathy, or bleeding, and no patients required liver transplantation.
The novel 2-bag regimen was well tolerated, with just 2 patients experiencing minor anaphylactoid reactions consisting of flushing, facial redness, and itching.
The authors concluded that this alternative IV n-acetylcysteine dosing regimen appears to be effective and well tolerated among pediatric patients compared with the current FDA-approved regimen.
While this is a promising alternative, the evidence may not be sufficient to suggest that it is acceptable to use in all patients.
References
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.